Medicine
MS Contin 60 mg extended-release tablet
MS Contin 60 mg extended-release tablet is a prescription medicine containing Morphine for oral use, marketed by Rhodes Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted between 15° to 30°C (59° to 86°F)…
Key facts
- Active ingredient (INN)
- Morphine
- Brand
- MS Contin
- Strength
- 60 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- Rhodes Pharmaceuticals
- Manufacturer
- Rhodes Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted between 15° to 30°C (59° to 86°F). Store MS CONTIN securely and dispose of properly.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Schedule CII
- ATC code
- N02AA01 Morphine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 May 2017
- Identifiers
- RxCUI 891881, 891888, 891893 +3DailyMed set ID c354b3bf-86c0-4bb8-8b1f-be2164942698NDC 42858-760Application NDA019516
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated, extended release in 1 bottle, plastic | 42858-760-01 | Rhodes Pharmaceuticals | 15 May 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 18 September 1984 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Morphine 60 mg extended-release tablet.
Other strengths and forms of Morphine
Clinical summary
Morphine is an opioid agonist indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which less invasive means of controlling pain are inadequate. MedsAcross supplies Morphine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MorphineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- INFUMORPH 200 prescribing information (Hikma Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need MS Contin 60 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.